By Colin Kellaher
Shares of Nuvalent surged in premarket trading Tuesday after the clinical-stage biopharmaceutical company agreed to be acquired by U.K. pharmaceutical company GSK for $10.6 billion.
GSK is paying $124 a share in cash for Nuvalent, a 40% premium to Monday's closing price of $88.49 for the Cambridge, Mass., company.
The deal is slated to close in the third quarter.
Nuvalent shares were recently up more than 38% to $122.51 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 09, 2026 05:45 ET (09:45 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.